PT-141 (Bremelanotide) in Bangkok, Thailand

PT-141, also known as bremelanotide, is a synthetic melanocortin peptide studied for its effects on sexual desire and arousal. Unlike sildenafil or tadalafil, which primarily improve penile blood flow through PDE5 (phosphodiesterase type 5) inhibition, bremelanotide is believed to act through melanocortin pathways in the central nervous system.

In the United States, bremelanotide injection is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, when low sexual desire causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance. Vyleesi is not approved for men, for postmenopausal women, or to enhance sexual performance.

At H.U.M. Clinic, PT-141 may be considered for selected patients, as part of our peptide therapy service, after physician assessment. Available formulations include subcutaneous injection and nasal spray.

Patients interested in PT-141 can book a consultation with our Thai-licensed, English-speaking physicians in Bangkok to review sexual-health concerns, medical history, treatment goals, and product suitability.

How PT-141 / Bremelanotide Works

Bremelanotide is a melanocortin receptor agonist. Its effects are believed to involve central pathways associated with sexual motivation and arousal rather than directly increasing genital blood flow.

This makes PT-141 fundamentally different from sildenafil and tadalafil. PDE5 inhibitors primarily act on vascular mechanisms, while bremelanotide acts through neurological signaling.

Bremelanotide does not directly increase testosterone and should not be described as a testosterone replacement or general aphrodisiac.

What Do Clinical Studies Show?

The pivotal evidence for bremelanotide comes from the RECONNECT Phase 3 trials, two randomized, double-blind, placebo-controlled studies involving 1,267 premenopausal women with HSDD.

Participants received bremelanotide 1.75 mg subcutaneously or placebo as needed for 24 weeks. Compared with placebo, bremelanotide produced statistically significant improvements in sexual-desire scores and reductions in distress associated with low sexual desire. In the integrated analysis, the improvement versus placebo was 0.35 points in the FSFI (Female Sexual Function Index) desire domain (on a 1.2 to 6.0 scale), while distress related to low desire (on a 0 to 4 scale) improved by 0.33 points versus placebo.

What Does the Evidence Show for PT-141 Nasal Spray?

Intranasal PT-141 was investigated before development shifted toward the subcutaneous formulation.

A randomized, double-blind, placebo-controlled study in 342 men with erectile dysfunction (ED) who had not responded to sildenafil evaluated 10 mg intranasal bremelanotide before sexual activity.

Positive clinical responses occurred in 33.5% of men receiving intranasal bremelanotide compared with 8.5% receiving placebo, with significantly greater intercourse satisfaction in the bremelanotide group. In 2023, the Journal of Urology published an expression of concern about this study, so these results should be interpreted with caution.

Another double-blind study in healthy men and in men with mild-to-moderate ED who had responded to sildenafil found significant erectile responses with intranasal PT-141 at doses above 7 mg, with the first erectile response occurring at approximately 30 minutes.

PT-141 Injection vs Nasal Spray

Feature	Subcutaneous (SC) Injection	Nasal Spray
Route	Under the skin	Intranasal
Studied timing	≥45 min before activity	45 minutes to 2 hours before sexual stimulation in one study; first erection about 30 minutes after dosing in another
Dose delivery	Measured dose prepared for subcutaneous injection	May vary with formulation and nasal technique
Convenience	Requires injection	Needle-free
Main limitation	Injection and nausea	Less-established clinical evidence; flushing and nausea also reported

For Vyleesi, the US FDA-approved regimen for premenopausal women with HSDD is 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than eight doses per month recommended.

H.U.M. Clinic’s 10 mg vial is a different product from the Vyleesi autoinjector, and 10 mg describes the total amount of bremelanotide in the vial, not a recommended single dose. Individual dosing and preparation must be determined by the prescribing physician.

For nasal spray, the number of sprays required and the timing of use must also be determined by the prescribing physician. Doses and timings used in studies are not dosing instructions for H.U.M. Clinic’s products.

PT-141 Price at H.U.M. Clinic in Bangkok

Current product options include:

• PT-141 (Bremelanotide) injection, 10 mg vial: THB 2,490
• PT-141 (Bremelanotide) nasal spray, 2.5 mg/spray, 60 sprays: THB 4,690

Prices and availability may change.

Online Consultation and Delivery in Thailand

Patients interested in PT-141 may visit H.U.M. Clinic in Bangkok or arrange an online consultation when appropriate.

The process is:

1. Book a doctor consultation

Patients can book an H.U.M. Clinic consultation here.

The physician reviews sexual-health concerns, medications, blood pressure, cardiovascular history, hormones when indicated, and previous treatments.

2. Review PT-141 suitability

The doctor determines whether bremelanotide is medically appropriate and discusses injection versus nasal formulation.

3. Select the prescribed product

If appropriate, treatment is prescribed with individualized instructions.

4. Arrange delivery

Eligible prescribed products may be arranged for domestic or local delivery in Thailand according to product storage and handling requirements.

Safety Review Before PT-141

Bremelanotide can temporarily increase blood pressure and reduce heart rate. The FDA-approved injection is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.

Common adverse effects include nausea, flushing, headache, vomiting, and injection-site reactions. Focal skin or gum hyperpigmentation can also occur, particularly with frequent exposure and in people with darker skin, and it may not resolve in every patient after stopping treatment.

The US label for Vyleesi notes that it may slow stomach emptying, which may reduce the absorption of oral medicines taken at the same time. It also advises avoiding use with oral naltrexone taken for alcohol or opioid addiction, and advises women who could become pregnant to use effective contraception and to stop treatment if pregnancy is suspected.

FAQ About PT-141 in Thailand

Medical Disclaimer

This article is for general medical information only and does not replace consultation with a licensed physician. PT-141 suitability, formulation, preparation, dose, frequency, and monitoring should be determined after medical evaluation.

References

Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500.

Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. Journal of Urology. 2008;179(3):1066-1071. doi:10.1016/j.juro.2007.10.063. PMID: 18206919. Expression of concern: Journal of Urology. 2023. doi:10.1097/JU.0000000000003117.

Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1):51-59. doi:10.1038/sj.ijir.3901139.

Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide injection), for subcutaneous use: prescribing information. DailyMed, U.S. National Library of Medicine. Revised March 2024.